Disclosures for "Clinical Relevance of Donanemab Treatment"
-
Dr. Atri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prothena. Dr. Atri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Atri has received personal compensation in the range of $0-$499 for serving as a Consultant for Qynapse. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Atri has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lunbeck. The institution of Dr. Atri has received research support from National Institute of Aging (NIA). The institution of Dr. Atri has received research support from AZ Department of Health Services. The institution of Dr. Atri has received research support from Gates Ventures. The institution of Dr. Atri has received research support from Multiple companies, universities & consortia for contracted clinical trials to institution. The institution of Dr. Atri has received research support from Washington University in St. Louis. Dr. Atri has received publishing royalties from a publication relating to health care.
-
Dr. Wessels has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Wessels has received stock or an ownership interest from Eli Lilly and Company.
-
Dr. Doty has received personal compensation for serving as an employee of Eli Lilly and Company, USA. Dr. Doty has received stock or an ownership interest from Eli Lilly and Company, USA.
-
Dr. Atkins has received personal compensation for serving as an employee of Eli Lilly. Dr. Atkins has received personal compensation for serving as an employee of WCG VeraSci. Dr. Atkins has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for WCG VeraSci. Dr. Atkins has stock in Eli Lilly. The institution of Dr. Atkins has received research support from NIMH. The institution of Dr. Atkins has received research support from WCG VeraSci. The institution of Dr. Atkins has received research support from WCG VeraSci.
-
Julie Chandler has received personal compensation for serving as an employee of Eli Lilly and Co. Julie Chandler has stock in Eli Lilly and Co.
-
Ming Lu has received personal compensation for serving as an employee of Eli Lilly and Company. Ming Lu has received stock or an ownership interest from Eli Lilly and Company.
-
Dr. Ye has nothing to disclose.
-
Ellen Dennehy has received personal compensation for serving as an employee of Eli Lilly. Ellen Dennehy has stock in Eli Lilly.
-
An immediate family member of Dr. Brooks has received personal compensation for serving as an employee of Indiana Hospital Association. Dr. Brooks has received stock or an ownership interest from Eli Lilly and Company.
-
Dr. Sims has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Sims has stock in Eli Lilly and Company.